A groundbreaking AI model named ActFound has been developed by scientists from China and the US to enhance drug discovery. This model surpasses existing AI models and traditional methods in bioactivity prediction, offering a more cost-effective solution. ActFound's ability to function with fewer data points addresses significant challenges in the drug development process.
The model utilizes advanced techniques like meta-learning and pairwise learning to improve prediction accuracy. ActFound was trained on a vast dataset, making it a promising tool for identifying useful compounds in drug discovery. Its performance in real-world applications, particularly in predicting cancer drug bioactivity, highlights its potential impact on the pharmaceutical industry.
• ActFound outperforms traditional methods in drug bioactivity prediction.
• The model uses meta-learning and pairwise learning for enhanced accuracy.
It is crucial for evaluating potential drug candidates in the development process.
It is particularly useful in drug discovery where data is often scarce and expensive to obtain.
This approach helps generalize predictions across different assays.
Its collaboration in creating ActFound showcases its commitment to advancing drug discovery through AI.
Isomorphic Labs, the AI drug discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600
How to level up your teaching with AI. Discover how to use clones and GPTs in your classroom—personalized AI teaching is the future.
Trump's Third Term? AI already knows how this can be done. A study shows how OpenAI, Grok, DeepSeek & Google outline ways to dismantle U.S. democracy.
Sam Altman today revealed that OpenAI will release an open weight artificial intelligence model in the coming months. "We are excited to release a powerful new open-weight language model with reasoning in the coming months," Altman wrote on X.